Immune Design Corp.
GLA monotherapy for use in cancer treatment
Last updated:
Abstract:
The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.
Status:
Grant
Type:
Utility
Filling date:
20 May 2019
Issue date:
4 May 2021